SageView Advisory Group LLC Purchases New Stake in Novo Nordisk A/S $NVO

SageView Advisory Group LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 25,516 shares of the company’s stock, valued at approximately $1,416,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Beacon Financial Group lifted its holdings in shares of Novo Nordisk A/S by 4.3% in the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after purchasing an additional 178 shares in the last quarter. Kavar Capital Partners Group LLC lifted its holdings in shares of Novo Nordisk A/S by 0.6% during the third quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock valued at $1,811,000 after acquiring an additional 200 shares during the period. SeaBridge Investment Advisors LLC boosted its position in Novo Nordisk A/S by 5.7% in the 3rd quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock valued at $207,000 after buying an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC raised its position in shares of Novo Nordisk A/S by 1.0% during the third quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 200 shares during the period. Finally, Revolve Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deal with Hims & Hers resolves a legal feud and opens the telehealth channel to sell FDA‑approved Ozempic and Wegovy, which could shift patients away from compounded alternatives and support volume recovery. Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
• Neutral Sentiment: India’s regulator warned against direct or surrogate advertising for weight‑loss drugs, which could constrain marketing strategies in a fast‑growing market but is not an immediate sales sanction. India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide (Ozempic/Wegovy), citing potential unreported serious events including deaths and a suicide — this raises regulatory risk and a near‑term compliance/oversight overhang. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: Sell‑side and street pressure: TD Cowen downgraded NVO and other analysts flag that the pipeline may not blunt semaglutide loss‑of‑exclusivity (LOE) headwinds — reinforcing negative sentiment after guidance cuts. Novo Nordisk downgraded as pipeline ‘not poised to blunt semaglutide LOE’
• Negative Sentiment: Investor legal pressure: law firm Pomerantz announced an investigation into Novo Nordisk investors, signaling possible litigation risk and additional headline volatility. Pomerantz law firm investigates claims on behalf of investors of Novo Nordisk
• Negative Sentiment: Competitive pressure: Eli Lilly’s aggressive investments and programs (including China expansion and employer/coverage initiatives) keep the GLP‑1 market intensely competitive, which could pressure Novo’s pricing and market share over time. The Real Reason Eli Lilly Is Pouring $3 Billion Into China

Novo Nordisk A/S Stock Up 0.2%

NVO stock opened at $38.82 on Thursday. The firm has a market cap of $173.31 billion, a PE ratio of 11.19 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm’s fifty day moving average is $50.69 and its 200 day moving average is $52.02. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $82.57.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 52.74%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NVO. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. TD Cowen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a report on Tuesday. Finally, Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Four research analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $49.93.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.